The estimated Net Worth of Perry B Molinoff is at least $15.7 Thousand dollars as of 24 December 2012. Perry Molinoff owns over 10,000 units of Palatin Technologies stock worth over $15,730 and over the last 22 years Perry sold PTN stock worth over $0.
Perry has made over 1 trades of the Palatin Technologies stock since 2012, according to the Form 4 filled with the SEC. Most recently Perry bought 10,000 units of PTN stock worth $6,100 on 24 December 2012.
The largest trade Perry's ever made was buying 10,000 units of Palatin Technologies stock on 24 December 2012 worth over $6,100. On average, Perry trades about 625 units every 0 days since 2002. As of 24 December 2012 Perry still owns at least 11,000 units of Palatin Technologies stock.
You can see the complete history of Perry Molinoff stock trades at the bottom of the page.
Perry's mailing address filed with the SEC is , , , , .
Over the last 22 years, insiders at Palatin Technologies have traded over $3,929,269 worth of Palatin Technologies stock and bought 390,692 units worth $374,235 . The most active insiders traders include Austin W & Greenhouse David..., Partners L P/Ilbiotechnolog..., and Carl Spana. On average, Palatin Technologies executives and independent directors trade stock every 76 days with the average trade being worth of $128,497. The most recent stock trade was executed by Stephen T Wills on 1 August 2024, trading 4,999 units of PTN stock currently worth $8,298.
palatin technologies, inc., a specialized biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the united states. the company's lead product is vyleesi, a melanocortin receptor agonist for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder. it is also developing oral pl8177, a selective melanocortin receptor (mcr) 1 agonist peptide that has completed phase i clinical trial for the treatment of inflammatory bowel diseases; and systemic pl8177, which has completed phase i clinical trial for treating non-infectious uveitis and covid-19. in addition, the company engages in the development of pl9643, a peptide melanocortin agonist active at multiple mcrs, including mc1r and mc5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. further, it is developing pl3994, a natriuretic peptide receptor (npr)-a agonist and sy
Palatin Technologies executives and other stock owners filed with the SEC include: